Andolast

Andolast (CR 2039) is an anti-allergic agent. Andolast can inhibit cAMP-phosphodiesterase with an IC50 value of 50 μM. Andolast can be used for the research of asthma[1].

Product Specifications

CAS Number

[143330-46-5]

Product Name Alternative

CR 2039; Dizolast

UNSPSC

12352005

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/andolast.html

Solubility

DMSO : 11.36 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CC=C(C2=NN=NN2)C=C1)NC3=CC=C(C4=NN=NN4)C=C3.[Na].[Na]

Molecular Formula

C15H11N9Na2O

Molecular Weight

379.29

References & Citations

[1]Revel L, Colombo S, Ferrari F, Folco G, Rovati LC, Makovec F. CR 2039, a new bis- (1H-tetrazol-5-yl) phenylbenzamide derivative with potential for the topical treatment of asthma. Eur J Pharmacol. 1992;229 (1) :45-53.|[2]Czuczwar SJ, Gasior M, Kozicka M, Pietrasiewicz T, Turski WA, Kleinrok Z. A potential anti-asthmatic drug, CR 2039, enhances the anticonvulsive activity of some antiepileptic drugs against pentetrazol in mice. Eur Neuropsychopharmacol. 1998;8 (3) :233-238.